FDA NDC Directory · JSON-LD · Markdown

Skyrizi

NDC 0074-5015 · HUMAN PRESCRIPTION DRUG · INJECTION

Generic namerisankizumab-rzaa
Labeler / ManufacturerAbbVie Inc.
Marketing categoryBiologic License Application · App BLA761262
Dosage form / routeINJECTION · INTRAVENOUS
Active ingredientsRISANKIZUMAB (600 mg/10mL)
Marketing started20220616
Package count2

External sources

Source: openFDA. Public-domain (CC0).